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Introduction {#ijc32489-sec-0001}
============

*KRAS*, *NRAS* and *BRAF* and DNA mismatch repair (MMR) status have become important biomarkers to evaluate colorectal cancer (CRC). *KRAS* mutations are widely observed in patients with resistance to antiepidermal growth factor receptor (EGFR) therapy and associated with poor prognosis in advanced or recurrent CRC.[1](#ijc32489-bib-0001){ref-type="ref"}, [2](#ijc32489-bib-0002){ref-type="ref"}, [3](#ijc32489-bib-0003){ref-type="ref"} *NRAS* mutations are rare and the clinicopathologic features, prognosis and treatment approaches for patients with *NRAS* mutations are unclear.[4](#ijc32489-bib-0004){ref-type="ref"}, [5](#ijc32489-bib-0005){ref-type="ref"} *BRAF* mutations are known as an indicator of poor prognosis and negative predictive biomarkers of anti‐EGFR therapy in advanced CRC.[6](#ijc32489-bib-0006){ref-type="ref"}, [7](#ijc32489-bib-0007){ref-type="ref"}, [8](#ijc32489-bib-0008){ref-type="ref"}, [9](#ijc32489-bib-0009){ref-type="ref"}, [10](#ijc32489-bib-0010){ref-type="ref"}

Detection strategies and clinical significances of these genes for tumors at specific stages remain unclear since most studies and guidelines focus on patients with recurrence or metastasis and typically detect one or two genes instead of including all the biomarkers above. Accordingly, the prognostic value of mutations at relatively early stages and utility of gene detection as a supplement to the TNM staging system are unclear.

We conducted a large retrospective study of cases with *KRAS*, *NRAS*, *BRAF* and MMR data at Fudan University Shanghai Cancer Center over the past 5 years to explore clinicopathologic features and prognosis. The results of our study can provide guidance for development of clinical strategies for gene detection.

Materials and Methods {#ijc32489-sec-0002}
=====================

Patients {#ijc32489-sec-0003}
--------

A database of patients underwent surgical treatment at the Department of Colorectal Surgery at the Shanghai Cancer Center from January 2013 to June 2018 was retrospectively reviewed. Gene information was found in 2,340 patients and 506 of them were confirmed with incomplete information of gene detection or clinicopathologic features. In total, 1,834 patients were included in the analysis. The treatment plans were designed based on the updated Chinese Ministry of Health guidelines for diagnosis and treatment of CRC and international guidelines.

Our study was conducted according to the principles of the Declaration of Helsinki and was approved by the Research Ethics Committee of the Fudan University Shanghai Cancer Center in China. All patients provided written informed consent for the use of their cancer tissue blocks for molecular analyses.

Mutation screening {#ijc32489-sec-0004}
------------------

The Department of Pathology of Fudan University Shanghai Cancer Center performed mutation detection in all cases using surgical cancer tissues. Sequencing was performed in 1,374 cases. *KRAS* exons 2--4, *NRAS* exons 2--4 and *BRAF* exon 15 were evaluated by bidirectional sequence using ABI 3730XL and a BigDye Terminator v. 3.1 Cycle Sequencing Kit (Applied Biosystems, Carlsbad, CA). Three independent experiments were performed to confirm the positive samples. DNA from the other 460 patients was tested using the AmoyDx KRAS/NRAS/BRAF Mutations Detection Kit (Amoy Diagnostics, Xiamen, China) under the principle of the amplification refractory mutation system (ARMS), covering the detection of KRAS mutations (exons 2--4), NRAS mutations (exons 2--4) and BRAF V600 mutations (exon 15). All results were confirmed according to the criterion suggested by the manufacturer.

Immunohistochemistry {#ijc32489-sec-0005}
--------------------

Mismatch repair gene deletion (dMMR) was determined by the absence of protein expression for any one of several genes, including hMLH1, hMSH2, hMSH6 or hPMS2. Immunohistochemistry was performed using the fully automated BenchMark ULTRA platform (Ventana Medical Systems, Inc., Tucson, AZ). Normal tissues adjacent to the tumor or lymphocytes in the stroma served as internal positive controls. Each result was confirmed by at least two experienced pathologists.

Statistical analysis {#ijc32489-sec-0006}
--------------------

All statistical analyses were performed by SPSS version 25.0 (IBM Corporation, Armonk, NY). Chi‐squared tests or Fisher\'s exact tests for categorical variables were used to compare the mutation status and clinical features. The Kolmogorov--Smirnov test was used to verify the normal distribution assumptions. The exploratory comparison of normally distributed and nonnormally distributed independent groups was performed using *t*‐tests and Mann--Whitney U tests (two groups). Overall survival (OS) was defined as the period of time between the first surgery and death from any cause. Analyses identifying prognostic predictors are performed using Cox proportional hazard models. Ten to fifteen predictors are necessary to proceed with multivariate survival analysis, whereby the selection for independent factors in the multivariate model was based on the univariate results. Log‐rank tests were employed to identify the associations between OS and predictors and all results are visualized by survival curves using the Kaplan--Meier method. A two‐sided *p*‐value \<0.05 was considered statistically significant.

Results {#ijc32489-sec-0007}
=======

Patients and mutations {#ijc32489-sec-0008}
----------------------

Basic information for 1,834 patients is summarized in Table [1](#ijc32489-tbl-0001){ref-type="table"}. One case of both *KRAS* and *NRAS* mutations, two cases of *KRAS* and *BRAF* mutations and three cases of *NRAS* and *BRAF* mutations were excluded from the prognostic analysis.

###### 

Clinical characteristics of 1,834 patients

  Variables                    *n* (%)
  ---------------------------- --------------
  Sex                          
  Male                         1,088 (59.3)
  Female                       746 (40.7)
  Age                          60.2 ± 11.9
  Tumor site                   
  Cecum                        43 (2.3)
  Ascending colon              277 (15.1)
  Hepatic flexure              70 (3.8)
  Transverse colon             76 (4.1)
  Splenic flexure              40 (2.2)
  Descending flexure           71 (3.9)
  Sigmoid colon                437 (23.8)
  Rectum                       805 (43.9)
  Multisite tumors             15 (0.8)
  Tumor size (cm)              4.3 ± 1.9
  TNM stage                    
  I                            192 (10.5)
  II                           502 (27.4)
  III                          758 (41.3)
  IV                           382 (20.8)
  Histological                 
  Ulcer type                   1,219 (66.5)
  Tumor type                   532 (29.0)
  Invasive type                83 (4.5)
  Pathology                    
  Adenocarcinoma               1,645 (89.7)
  Mucinous carcinoma           189 (10.3)
  Differentiation              
  G3--G4                       557 (30.4)
  G1--G2                       1,277 (69.6)
  Lymphovascular Invasion +    698 (38.1)
  Perineural Invasion +        694 (37.8)
  Extranodal tumor deposit +   401 (21.9)
  *KRAS* mutant                851 (46.4)
  *NRAS* mutant                58 (3.2)
  *BRAF* mutant                65 (3.5)
  dMMR                         102 (5.6)

Clinicopathologic features {#ijc32489-sec-0009}
--------------------------

Univariate analyses of clinicopathologic features according to mutations in *KRAS*, *NRAS* and *BRAF* and DNA MMR status are listed in Table [2](#ijc32489-tbl-0002){ref-type="table"}.

###### 

Univariate analysis of clinicopathologic features

  Variables                                           *KRAS*        *NRAS*        *BRAF*      MMR                                                                                                           
  --------------------------------------------------- ------------- ------------- ----------- -------------- ------------ ----------- -------------- ------------- ----------- -------------- ------------- -----------
  Sex                                                                             **0.008**                               0.70                                     **0.001**                                0.47
  Male                                                611 (56.2)    477 (43.8)                1,055 (97.0)   33 (3.0)                 1,062 (97.6)   26 (2.4)                  1,024 (94.1)   64 (5.9)      
  Female                                              372 (49.9)    374 (50.1)                721 (96.7)     25 (3.3)                 707 (94.8)     39 (5.2)                  708 (95.0)     38 (5.0)      
  Age                                                 59.5 ± 11.9   60.8 ± 11.9   **0.023**   60.1 ± 12.0    61.8 ± 9.4   0.17        60.1 ± 11.8    60.0 ± 13.9   0.96        60 ± 11.7      55.2 ± 14.1   **0.001**
  Tumor site[1](#ijc32489-note-0004){ref-type="fn"}                               0.061                                   0.170                                    **0.001**                                **0.001**
  Cecum                                               15 (34.9)     28 (65.1)                 41 (95.3)      2 (4.7)                  41 (95.3)      2 (4.7)                   39 (90.7)      4 (9.3)       
  Ascending colon                                     115 (41.5)    162 (58.5)                269 (97.1)     8 (2.9)                  256 (92.4)     21 (7.6)                  242 (87.4)     35 (12.6)     
  Hepatic flexure                                     34 (48.6)     36 (51.4)                 69 (98.6)      1 (1.4)                  65 (92.9)      5 (7.1)                   56 (80.0)      14 (20.0)     
  Transverse colon                                    43 (56.6)     33 (43.4)                 75 (98.7)      1 (1.3)                  73 (96.1)      3 (3.9)                   63 (82.9)      13 (17.1)     
  Splenic flexure                                     22 (55.0)     18 (45.0)                 40 (100)       0 (0)                    38 (95.0)      2 (5.0)                   35 (87.5)      5 (12.5)      
  Descending flexure                                  46 (64.8)     25 (35.2)                 70 (98.6)      1 (1.4)                  67 (94.4)      4 (5.6)                   63 (88.7)      8 (11.3)      
  Sigmoid colon                                       279 (63.8)    158 (36.2)                423 (96.8)     14 (3.2)                 427 (97.7)     10 (2.3)                  432 (98.9)     5 (1.1)       
  Rectum                                              423 (52.5)    382 (47.5)                774 (96.1)     31 (3.9)                 787 (97.8)     18 (2.2)                  790 (98.1)     15 (1.9)      
  Tumor size (cm)                                     4.2 ± 1.9     4.4 ± 2.0     **0.026**   4.3 ± 2.0      3.8 ± 1.9    **0.049**   4.3 ± 1.9      4.6 ± 1.9     0.26        4.2 ± 1.9      5.9 ± 3.0     **0.001**
  T stage                                                                         0.56                                    0.76                                     0.80                                     0.82
  T1                                                  32 (57.1)     24 (42.9)                 53 (94.7)      3 (5.3)                  54 (96.5)      2 (3.5)                   54 (96.5)      2 (3.5)       
  T2                                                  135 (57.2)    101 (42.8)                230 (97.5)     6 (2.5)                  228 (96.6)     8 (3.4)                   223 (94.5)     13 (5.5)      
  T3                                                  550 (52.5)    498 (47.5)                1,015 (96.9)   33 (3.1)                 1,014 (96.7)   34 (3.3)                  986 (94.1)     62 (5.9)      
  T4                                                  266 (53.8)    228 (46.2)                478 (96.7)     16 (3.3)                 473 (95.7)     21 (4.3)                  469 (94.9)     25 (5.1)      
  N stage                                                                         0.15                                    0.18                                     **0.005**                                **0.001**
  N0                                                  421 (55.6)    336 (44.4)                738 (97.5)     19 (2.5)                 741 (97.9)     16 (2.1)                  693 (91.6)     64 (8.4)      
  N+                                                  562 (52.2)    515 (47.8)                1,038 (96.4)   39 (3.6)                 1,028 (95.4)   49 (4.6)                  1,039 (96.5)   38 (3.5)      
  M stage                                                                         0.22                                    0.76                                     **0.044**                                **0.002**
  M0                                                  789 (54.3)    663 (45.7)                1,407 (96.9)   45 (3.1)                 1,407 (96.8)   45 (3.2)                  1,359 (93.6)   93 (6.4)      
  M1                                                  194 (50.8)    188 (49.2)                369 (96.7)     13 (3.3)                 362 (94.9)     20 (5.1)                  373 (97.5)     9 (2.5)       
  TNM stage                                                                       0.27                                    0.35                                     **0.014**                                **0.001**
  I                                                   115 (59.9)    77 (40.1)                 184 (95.9)     8 (4.1)                  184 (95.9)     8 (4.1)                   181 (94.3)     11 (5.7)      
  II                                                  270 (53.7)    232 (46.3)                492 (98.0)     10 (2.0                  495 (98.6)     7 (1.4)                   452 (90.1)     50 (9.9)      
  III                                                 404 (53.3)    354 (46.7)                731 (96.4)     27 (3.6)                 728 (96.0)     30 (4.0)                  726 (95.8)     32 (4.2)      
  IV                                                  194 (50.8)    188 (49.2)                369 (96.7)     13 (3.3)                 362 (94.9)     20 (5.1)                  373 (97.5)     9 (2.5)       
  Histological                                        983           851           **0.001**                               0.21                                     0.52                                     0.15
  Ulcer type                                          691 (56.7)    528 (43.3)                1,177 (96.5)   42 (3.5)                 1,176 (96.5)   43 (3.5)                  1,155 (94.7)   64 (5.3)      
  Tumor type                                          244 (45.9)    288 (54.1)                518 (97.4)     14 (2.6)                 514 (96.6)     18 (3.4)                  496 (93.2)     36 (6.8)      
  Invasive type                                       48 (57.8)     35 (42.5)                 81 (97.6)      2 (2.4)                  79 (95.2)      4 (4.8)                   81 (97.6)      2 (2.4)       
  Pathology                                                                       **0.001**                               0.68                                     0.17                                     **0.001**
  Adenocarcinoma                                      898 (54.6)    747 (45.4)                1,592 (97.1)   53 (2.9)                 1,590 (96.7)   55 (3.3)                  1,569 (95.4)   76 (4.6)      
  Mucinous carcinoma                                  85 (45.2)     104 (54.8)                184 (97.4)     5 (2.6)                  179 (94.7)     10 (5.3)                  163 (86.2)     26 (13.8)     
  Differentiation                                                                 0.17                                    0.70                                     **0.001**                                **0.001**
  G3--G4                                              291 (52.2)    266 (47.8)                541 (97.1)     16 (2.9)                 518 (93.0)     39 (7.0)                  502 (90.1)     55 (9.9)      
  G1--G2                                              692 (54.2)    585 (45.8)                1,235 (96.7)   42 (3.3)                 1,251 (98.0)   26 (2.0)                  1,230 (96.3)   47 (3.7)      
  Lymphovascular Invasion                                                         0.77                                    0.58                                     **0.001**                                0.17
  Negative                                            615 (54.1)    521 (45.9)                1,101 (97.0)   35 (3.0)                 1,108 (97.5)   28 (2.5)                  1,064 (93.7)   72 (6.3)      
  Positive                                            368 (52.7)    330 (47.3)                675 (96.7)     23 (3.3)                 661 (94.7)     37 (5.3)                  668 (95.7)     30 (4.3)      
  Perineural Invasion                                                             0.41                                    0.40                                     0.07                                     **0.002**
  Negative                                            618 (54.2)    522 (45.8)                1,107 (97.1)   33 (2.9)                 1,106 (97.0)   34 (3.0)                  1,062 (93.2)   78 (6.8)      
  Positive                                            365 (52.6)    329 (47.4)                669 (96.3)     25 (3.7)                 663 (95.5)     31 (4.5)                  670 (96.5)     24 (3.5)      
  Extranodal tumor deposit                                                        0.055                                   0.52                                     **0.001**                                **0.002**
  Negative                                            785 (54.8)    648 (45.2)                1,390 (97.0)   43 (3.0)                 1,394 (97.3)   39 (2.7)                  1,341 (93.6)   92 (6.4)      
  Positive                                            198 (49.3)    203 (50.7)                386 (96.3)     15 (3.7)                 375 (93.5)     26 (6.5)                  391 (97.5)     10 (2.5)      

Another 15 patients with multisite tumors were excluded.

Results of the multivariate analysis are summarized in Table [3](#ijc32489-tbl-0003){ref-type="table"}. Only tumor size was associated with *NRAS* mutations in the univariate analysis. Therefore, *NRAS* mutations were excluded from the multivariate analysis. *KRAS* mutation rate was high for the following factors: female, advanced age, tumor type histology, mucinous carcinoma and positive tumor deposits. *BRAF* showed a high mutation rate in female, poor differentiation, lymphovascular invasion and positive tumor deposits. A high rate of dMMR was associated with low age, large tumor size, poor differentiation and Stages I--III. Tumor site was independently associated with *KRAS* mutation, *BRAF* mutation and dMMR.

###### 

Multivariate analysis of clinicopathologic features

  Variables                  *KRAS* mutant   *BRAF* mutant   dMMR                                                              
  -------------------------- --------------- --------------- ----------- ------ ------------ ----------- ------- ------------- -----------
  Sex                                                                                                                          
  Female                     1               Ref                         1      Ref                                            
  Male                       0.81            0.66--0.99      **0.045**   0.57   0.34--0.97   **0.039**                         
  Age                        1.01            1.01--1.02      **0.005**                                   0.97    0.95--0.98    **0.001**
  Tumor site                 0.92            0.88--0.96      **0.001**   0.81   0.73--0.90   **0.001**   0.71    0.64--0.78    **0.001**
  Tumor size                                                                                             1.29    1.17--1.42    **0.001**
  Histology                                                                                                                    
  Ulcer type                 1               Ref                                                                               
  Tumor type                 1.63            1.31--2.04      **0.001**                                                         
  Invasive type              0.91            0.53--1.56      0.726                                                             
  Pathology                                                                                                                    
  Adenocarcinoma             0.66            0.47--0.94      **0.021**                                                         
  Mucinous carcinoma         1               Ref                                                                               
  Differentiation                                                                                                              
  G3--G4                                                                 2.33   1.31--4.14   **0.004**   2.74    1.66--4.51    **0.001**
  G1--G2                                                                 1      Ref                      1       Ref           
  Lymphovascular Invasion                                                1.86   1.02--3.50   **0.043**                         
  Perineural Invasion                                                                                                          
  Extranodal tumor deposit   1.39            1.10--1.76      **0.008**   2.28   1.29--4.05   **0.005**                         
  TNM Stage                                                                                                                    
  I                                                                                                      13.71   4.64--40.45   **0.001**
  II                                                                                                     8.55    3.58--20.47   **0.001**
  III                                                                                                    2.92    1.22--6.98    **0.016**
  IV                                                                                                     1       Ref           

Survival analysis {#ijc32489-sec-0010}
-----------------

In a univariate analysis of Stage I--IV tumors, *KRAS*‐mutated tumors and *BRAF*‐mutated tumors were associated with a shorter OS compared to that of all‐wild‐type tumors. There was no significant difference in OS between *NRAS*‐mutated tumors and all‐wild‐type tumors (Fig. [1](#ijc32489-fig-0001){ref-type="fig"}). Table [4](#ijc32489-tbl-0004){ref-type="table"} presents the results obtained from the Cox analysis of prognostic actors.

![Kaplan--Meier analysis of OS at (*a*) Stages I--IV, (*b*) Stages I--II, (*c*) Stage III and (*d*) Stage IV. Each *p*‐value reflects its respective mutation compared with all‐wild‐type.](IJC-145-1625-g001){#ijc32489-fig-0001}

###### 

Cox analysis of prognostic actors for OS in patients from Stage I to Stage IV

  Prognosis variables        Stages I--II   Stage III            Stage IV                                    
  -------------------------- -------------- -------------------- ----------- ------------------- ----------- -------------------
  Sex (female)               **0.088**      0.26 (0.06--1.22)    0.20        0.74 (0.46--1.18)   0.43        1.18 (0.79--1.76)
  Age                        0.41           1.02 (0.97--1.07)    0.86        1.00 (0.98--1.02)   0.96        1.00 (0.98--1.02)
  Tumor site                 0.79           0.97 (0.77--1.21)    0.71        1.02 (0.92--1.13)   **0.013**   0.91 (0.84--0.98)
  Tumor size                 **0.001**      1.44 (1.21--1.73)    **0.001**   1.40 (1.24--1.58)   **0.047**   1.10 (1.01--1.21)
  Histology                                                                                                  
  Tumor type                 0.98           1.02 (0.33--3.12)    0.35        1.28 (0.76--2.15)   0.94        0.94 (0.58--1.53)
  Invasive                   --             --                   0.90        0.94 (0.37--2.42)   0.32        1.44 (0.70--2.99)
  Pathology (Mucinous)       0.83           0.75 (0.058--9.64)   0.35        1.33 (0.74--2.42)   0.48        0.79 (0.42--1.50)
  Differentiation (G1--G2)   0.98           1.02 (0.26--4.00)    **0.001**   0.30 (0.19--0.49)   **0.007**   0.59 (0.40--0.86)
  Lymphovascular Invasion    **0.04**       3.80 (1.06--13.54)   0.18        1.43 (0.85--2.39)   0.29        0.79 (0.51--1.22)
  Perineural Invasion        **0.001**      5.56 (2.01--15.41)   **0.008**   1.88 (1.18--2.99)   **0.017**   1.65 (1.09--2.49)
  Extranodal tumor deposit   --             --                   **0.006**   1.89 (1.20--2.97)   0.14        1.36 (0.91--2.04)
  *KRAS* mutant              0.76           1.20 (0.37--3.91)    0.13        1.47 (0.89--2.42)   **0.022**   1.60 (1.07--2.40)
  *NRAS* mutant              **0.025**      6.13 (1.25--30.01)   0.071       2.29 (0.93--5.66)   0.25        0.42 (0.10--1.81)
  *BRAF* mutant              --             --                   0.29        1.78 (0.61--5.22)   **0.003**   2.84 (1.43--5.67)
  dMMR                       0.20           2.73 (0.60--12.47)   **0.008**   0.12 (0.25--0.58)   0.67        0.72 (0.16--3.26)

Bold values indicate *p*‐values less than 0.05.

No differences in OS between *KRAS*‐mutated tumors and all‐wild‐type tumors of Stages I--II were detected in both the univariate analysis and multivariate analysis (Fig. [1](#ijc32489-fig-0001){ref-type="fig"} and Table [4](#ijc32489-tbl-0004){ref-type="table"}). In Stage III, *KRAS*‐mutated tumors were associated with a shorter OS than that of all‐wild‐type tumors in a univariate analysis but not in a multivariate analysis. In Stage IV, we observed a significant difference in OS between *KRAS*‐mutated tumors and all‐wild‐type tumors in both a univariate analysis and multivariate analysis.

In Stages I--II, OS was shorter for *NRAS*‐mutated tumors than for all‐wild‐type tumors in both the univariate analysis and multivariate analysis. No similar difference was observed in Stage III tumors in the univariate analysis or multivariate analysis or in Stage IV tumors in the univariate analysis or multivariate analysis.

No statistically significant difference in OS between patients with *BRAF*‐mutated tumors and all‐wild‐type tumors was observed for Stages I--II and Stage III in the univariate analysis. For Stage IV, the OS of patients with *BRAF*‐mutated tumors was shorter than that of patients with all‐wild‐type tumors in both univariate analysis and multivariate analysis.

In the Cox analysis, dMMR was independently associated with longer OS in Stage III but not Stage I--II or Stage IV tumors.

Discussion {#ijc32489-sec-0011}
==========

We retrospectively analyzed mutations in *KRAS*, *NRAS* and *BRAF* and DNA MMR status of 1,834 patients with colorectal adenocarcinoma during the past 5 years at our institution. Comprehensive information, including clinicopathologic features and prognosis, was gathered to explore the necessity and optimization of gene detection for tumors with different clinicopathologic features and stages.

Relevant studies of relatively large populations are summarized in Table [5](#ijc32489-tbl-0005){ref-type="table"}.[5](#ijc32489-bib-0005){ref-type="ref"}, [7](#ijc32489-bib-0007){ref-type="ref"}, [8](#ijc32489-bib-0008){ref-type="ref"}, [11](#ijc32489-bib-0011){ref-type="ref"}, [12](#ijc32489-bib-0012){ref-type="ref"}, [13](#ijc32489-bib-0013){ref-type="ref"}, [14](#ijc32489-bib-0014){ref-type="ref"}, [15](#ijc32489-bib-0015){ref-type="ref"}, [16](#ijc32489-bib-0016){ref-type="ref"}, [17](#ijc32489-bib-0017){ref-type="ref"}, [18](#ijc32489-bib-0018){ref-type="ref"}, [19](#ijc32489-bib-0019){ref-type="ref"}, [20](#ijc32489-bib-0020){ref-type="ref"}, [21](#ijc32489-bib-0021){ref-type="ref"}, [22](#ijc32489-bib-0022){ref-type="ref"} The *KRAS* mutation rate in our study was similar to those in studies of Eastern and Western populations. As for *NRAS*, a low mutation rate was reported in most studies and only Stage IV cases are included. Interestingly, the *BRAF* mutation rate was lower in our study and other studies of Asian populations than in studies of Western populations. Turning now to DNA MMR status, immunohistochemical analyses and DNA sequencing are not 100% accurate for identifying dMMR/MSI. However, these two methods are highly consistent in results, that is, near 95%.[23](#ijc32489-bib-0023){ref-type="ref"} It is difficult to definitively determine the difference in dMMR rate between Eastern and Western populations based on available studies.

###### 

Clinical studies reporting rates of *KRAS*, *NRAS*, and *BRAF* mutations and dMMR/MSI

  Year            Author               Journal                 Number of centers   Area                 Number of patients   Stage     *KRAS* mutant rate   *NRAS* mutant rate   *BRAF* mutant rate   dMMR/MSI rate
  --------------- -------------------- ----------------------- ------------------- -------------------- -------------------- --------- -------------------- -------------------- -------------------- ---------------
  2005            Benatti *et al*.     Clin Cancer Res         3                   Italy                1,263                I--IV     --                   --                   --                   20.3%
  2007            Koopman *et al*.     Br J Cancer             Many (74)           The Netherlands      515                  IV        --                   --                   --                   3.5%
  2009            Des Guetz *et al*.   Eur J Cancer            Many                Many                 3,690                II--III   --                   --                   --                   13.7%
  2010            De Roock *et al*.    Lancet Oncol            11                  Europe               773                  IV        40.0%                2.6%                 4.7%                 --
  2011            Sinicrope *et al*.   J Natl Cancer Inst      Many                Europe and America   2,141                II--III   --                   --                   --                   16.1%
  2012            Imamura *et al*.     Clin Cancer Res         Many                U.S                  1,261                I--IV     35.3%                --                   14.4%                --
  2013            Douillard *et al*.   N Engl J Med            Many                Europe and America   1,096                IV        45.6%                7.5%                 8.3%                 --
  2014            Imamura *et al*.     Mol Cancer              Many                U.S                  1,267                I--IV     40.0%                                     14.5%                --
  2014            Schirripa *et al*.   Int J Cancer            1                   Italy                786                  IV        50.0%                6.0%                 9.2%                 --
  2016            Summers *et al*.     Clin Cancer Res         Many                UK and Ireland       2,157                IV        39.8%                4.0%                 9.5%                 4.6%
  2011            Yokota *et al*.      Br J Cancer             1                   Japan                229                  IV        34.5%                ‐                    6.5%                 --
  2014            Tong *et al*.        Cancer Biol Ther        1                   HK, China            1,506                --        44.5%                --                   --                   --
  2015            Zhang *et al*.       Sci Rep                 3                   China                1,110                I‐IV      45.4%                3.9%                 3.1%                 --
  2015            Kawazoe *et al*.     BMC Cancer              1                   Japan                264                  IV        37.9%                4.2%                 5.4%                 --
  2015            Yan *et al*.         World J Gastroenterol   1                   China                538                  I--IV     37.9%                --                   4.4%                 11.4%
  Current study   Guo *et al*.         Int J Cancer            1                   China                1,854                I--IV     46.4%                3.2%                 3.5%                 5.6%

Clinicopathologic factors related to a high *KRAS* mutation rate in our study were female, advanced age, tumor type histology, mucinous carcinoma and positive tumor deposits. However, Imamura *et al*. reported different results in a study of 1,267 patients. In their study, *KRAS* mutations were associated with male, well‐moderate differentiation, absent‐minimal peritumoral lymphocytic reaction.[16](#ijc32489-bib-0016){ref-type="ref"} Further studies are expected to explorer clinicopathologic features associated with *KRAS* mutations. No significant differences in clinicopathologic features were observed between *NRAS*‐mutated tumors and all‐wild‐type tumors in our study or other studies. A high *BRAF* mutation rate was associated with female, poor differentiation, lymphovascular invasion and positive tumor deposits in our study. Similar results were found in previous studies.[6](#ijc32489-bib-0006){ref-type="ref"}, [20](#ijc32489-bib-0020){ref-type="ref"} This is the first study to report that positive tumor deposits are independently related to *BRAF* mutations. Positive tumor deposits are associated with poor prognosis and have become a reference factor for TNM staging.[24](#ijc32489-bib-0024){ref-type="ref"}, [25](#ijc32489-bib-0025){ref-type="ref"} Our findings suggest that a high *BRAF* mutation rate is the main predictor of a poor prognosis in patients with positive tumor deposits. dMMR was relatively common in large, poor differentiated and Stage I--II tumors, as reported in previous studies.[11](#ijc32489-bib-0011){ref-type="ref"}, [22](#ijc32489-bib-0022){ref-type="ref"} However, we observed that the age of high incidence of dMMR was different in different population studies. Our results are consistent with other studies of Chinese populations, with a high dMMR rate in young individuals.[26](#ijc32489-bib-0026){ref-type="ref"}, [27](#ijc32489-bib-0027){ref-type="ref"} In studies of western populations, high dMMR rates appear to be associated with older age.[28](#ijc32489-bib-0028){ref-type="ref"}, [29](#ijc32489-bib-0029){ref-type="ref"}, [30](#ijc32489-bib-0030){ref-type="ref"}

In general, *KRAS* mutation rate decreased from right colon to left colon, but increased slightly in rectum. *BRAF* mutation rate was higher in right colon than left colon and lowest in rectum. The rate of dMMR increased gradually from cecum to hepatic flexure and then decreased from hepatic flexure to rectum. Yamauchi *et al*. reported that the rate of *KRAS* mutations was highest in cecal tumors and gradually decrease from cecal to transverse colon, but no obvious pattern of *KRAS* mutation rate was found from splenic flexure to rectum in their study.[31](#ijc32489-bib-0031){ref-type="ref"} Rosty *et al*. and Imamura *et al*. confirmed the highest *KRAS* mutation rate in cecal tumors.[16](#ijc32489-bib-0016){ref-type="ref"}, [32](#ijc32489-bib-0032){ref-type="ref"} Different site distribution of *KRAS* mutations might be caused by the fact that only *KRAS* exon 2 (codons 12 and 13) was sequenced in these previous studies. Yamauchi *et al*. also reported that the rates of MSI‐high and *BRAF* mutations gradually increased from the rectum to ascending colon, followed by falls in the cecum, which was similar to the trends in our results.[31](#ijc32489-bib-0031){ref-type="ref"}

Considering that mutations in *KRAS*, *NRAS* and *BRAF* and DNA MMR statuses are not all routinely tested in many clinical institutions, we suggest a gene detection strategy to be developed in future studies based on the clinicopathologic differences described above.

Poor prognosis and resistance to anti‐EGFR targeted therapy of *KRAS* mutations are defined in Stage IV patients.[33](#ijc32489-bib-0033){ref-type="ref"}, [34](#ijc32489-bib-0034){ref-type="ref"} However, in Stage I--III patients, the prognostic value of *KRAS* is controversial. Ogino *et al*. reported that the KRAS mutational status is not associated with DFS or OS in a study of 508 patients with Stage III CRC.[35](#ijc32489-bib-0035){ref-type="ref"} Similarly, Roth *et al*. reported that *KRAS* mutations do not have major prognostic value based on a study of 1,404 patients with Stage II--III CRC.[36](#ijc32489-bib-0036){ref-type="ref"} However, Hutchins *et al*. found that the risk of recurrence is significantly higher for *KRAS* mutants than wild‐type *KRAS* in the QUASAR study, which included 1,708 Stage II cases and 163 Stage III cases.[37](#ijc32489-bib-0037){ref-type="ref"} Taieb *et al*. evaluated 4,411 patients with Stage III colorectal and found that *BRAF* or *KRAS* mutations were independently associated with a shorter time to recurrence, survival after recurrence and OS in patients with MSS, but not in MSI tumors.[38](#ijc32489-bib-0038){ref-type="ref"} In the univariate analysis, prognosis was worse in *KRAS* mutants than all‐wild‐type cases and this could be explained by the increase in the rate of *KRAS* mutations as the tumor stage increased in our study (Table [2](#ijc32489-tbl-0002){ref-type="table"}).

Poor prognosis for *BRAF* mutation has been widely reported in Stage IV cases.[10](#ijc32489-bib-0010){ref-type="ref"} Similar results can be found in a few studies of Stage II or III patients.[38](#ijc32489-bib-0038){ref-type="ref"}, [39](#ijc32489-bib-0039){ref-type="ref"} Our statistical analyses showed that *BRAF* mutation is an independent risk factor for shorter OS only in Stage IV tumors but not Stage I--III tumors. The contradiction might be explained by the low incidence of *BRAF* mutation in the Asian population. Therefore, far fewer patients with Stage II--III *BRAF*‐mutated cancer were included in our study than in previous studies, resulting in statistically insignificant results.

Unlike *KRAS* and *BRAF* mutations, *NRAS* mutation is an independent risk factor for shorter OS in Stages I--II but not in Stage III or IV. A few studies have reported a poor prognosis associated with *NRAS* mutations.[8](#ijc32489-bib-0008){ref-type="ref"}, [40](#ijc32489-bib-0040){ref-type="ref"}, [41](#ijc32489-bib-0041){ref-type="ref"} However, very few studies reported the prognostic value of *NRAS* mutations at specific stages. In a retrospective study of patients with Stage IV CRC, Schirripa *et al*. reported that *NRAS* mutations are associated with a shorter OS than all‐wild‐type cases and more patients with *NRAS* mutations at Stage IV were included in their study than in ours (47 *vs*. 13).[5](#ijc32489-bib-0005){ref-type="ref"} Further studies of *NRAS* mutations are needed.

dMMR was an independent prognostic factor for a favorable prognosis for patients with Stage III cancer in our study. Similar conclusions are reached in a number of studies under certain conditions. Sinicrope *et al*. reported that dMMR is significantly associated with better survival after recurrence in patients with Stage III proximal colon cancers.[42](#ijc32489-bib-0042){ref-type="ref"} In a study of 1,254 patients with Stage II--IV cancer, Klingbiel *et al*.[43](#ijc32489-bib-0043){ref-type="ref"} reported that MSI‐H is associated with both longer relapse‐free survival and OS in Stage II patients and relapse‐free survival in Stage III patients. Differences in conclusions could be explained by different sample size and multivariate analysis methods.

In conclusion, mutations in *KRAS*, *NRAS* and *BRAF* and dMMR were associated with different clinicopathologic features. *KRAS* and *BRAF* mutations were independent risk factors for shorter OS in Stage IV tumors. *NRAS* mutations were an independent risk factor for shorter OS in Stage I--II tumors. dMMR was an independent protective factor for longer OS in Stage III tumors. The clinicopathologic features and prognostic values of these markers require further validation, especially in early‐stage patients.
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